Wound Management Market Value Forecasted To Reach US$ 26.2 Billion By 2027: Acumen Research And Consulting
April 07, 2021 11:51 ET
|
Acumen Research and Consulting
LOS ANGELES, April 07, 2021 (GLOBE NEWSWIRE) -- The Global Wound Management Market is expected to grow at a CAGR of around 4.7% from 2020 to 2027 and reach the market value of over US$ 26.2 Bn by...
DEBx Medical recibe la autorización de llevar la marca CE y la certificación ISO 13485 para Debrichem®, un novedoso gel desecante para el desbridamiento químico que inicia la cicatrización de heridas infectadas y crónicas
February 25, 2021 03:30 ET
|
DEBx Medical B.V.
Debrichem® ofrece un enfoque alternativo muy eficaz en el cuidado de las heridas crónicas, iniciando la cicatrización en más del 90% de los casos tras una sola aplicación1La marca CE y la...
DEBx Medical Receives CE Mark Clearance and ISO 13485 Certification for Debrichem®, a Novel Desiccant Gel for Chemical Debridement to Initiate Healing in Infected, Chronic Wounds
February 25, 2021 03:30 ET
|
DEBx Medical B.V.
Debrichem® offers a very effective, alternative approach to chronic wound care, initiating healing in more than 90 % of cases after one application1CE mark and ISO 13485:2016 certification are...
Arch Therapeutics Announces Closing of $6.9 Million Private Placement
February 18, 2021 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today...
Misonix Reports Fiscal 2021 Second Quarter Financial Results
February 04, 2021 16:01 ET
|
MISONIX, Inc.
FARMINGDALE, N.Y., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and...
Arch Therapeutics to Present at the H.C. Wainwright BioConnect Conference, January 11 - 14, 2021
January 05, 2021 07:55 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel self-assembling wound care and biosurgical devices, announced...
Arch Therapeutics Announces Distribution Agreement with Buffalo Supply, Inc.
January 04, 2021 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel self-assembling wound care and biosurgical devices, announced...
Misonix Announces the Second Largest U.S. Commercial Payer Has Provided Coverage for TheraSkin® to Treat All Lower Extremity Dermal Wounds Adding 32 Million New Covered Lives
December 18, 2020 10:14 ET
|
MISONIX, Inc.
FARMINGDALE, N.Y., Dec. 18, 2020 (GLOBE NEWSWIRE) -- 2020) – Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that...
Misonix Reports Preliminary Fiscal 2020 Fourth Quarter Revenue of Approximately $13.5 Million
July 10, 2020 07:00 ET
|
MISONIX, Inc.
Full Year Revenue of Approximately $62.3 Million Company Focus on Shareholder Value Creation, Cash Preservation, Expense Reduction, Workforce Efficiency and Operational Synergies FARMINGDALE,...
Misonix Fiscal 2020 Third Quarter Revenue Rises to $17.9 Million
May 11, 2020 16:05 ET
|
MISONIX, Inc.
FARMINGDALE, N.Y., May 11, 2020 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and...